Subtype
Prostate Neoplasm
CI-CAN-00003778Explore in graph →
Non-malignant1,453 active trials24 approved drugs58 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003778Explore in graph →
Clinical trials
6,544 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02420652 | Metformin Hydrochloride and Aspirin in Treating Patients With Hormone-Dependent Prostate Cancer That Has Progressed After Surgery or Radiation Therapy(PRIMA) | terminated | Phase 2 | 27 | Rutgers, The State University of New JerseyOTHER | 1 | Feb 8, 2023 | clinicaltrials |
| NCT02146833 | SHIP (Selinexor in Hormone Insensitive Prostate Cancer)(SHIP) | terminated | Phase 2 | 20 | Karyopharm Therapeutics IncINDUSTRY |
| 1 |
| Jan 26, 2023 |
| clinicaltrials |
| NCT04928820 | 68Ga-PSMA-11 PET/CT for the Diagnosis of Bone Metastases in Patients With Prostate Cancer and Biochemical Progression During Androgen Deprivation Therapy | terminated | Phase 2 | 22 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Oct 21, 2022 | clinicaltrials |
| NCT02766478 | Genistein Supplementation to Mitigate Cardiometabolic Dysfunction in Patients Undergoing Androgen Deprivation Therapy for Prostate Cancer(GeniPro) | terminated | Phase 2 | 10 | Emory UniversityOTHER | 1 | Sep 27, 2022 | clinicaltrials |
| NCT02203513 | A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer | terminated | Phase 2 | 111 | National Cancer Institute (NCI)NIH | 1 | Sep 10, 2022 | clinicaltrials |
| NCT03531827 | Combining CRLX101, a Nanoparticle Camptothecin, With Enzalutamide in People With Progressive Metastatic Castration Resistant Prostate Cancer Following Prior Enzalutamide Treatment | terminated | Phase 2 | 4 | National Cancer Institute (NCI)NIH | 1 | Jul 12, 2022 | clinicaltrials |
| NCT01681433 | OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone | terminated | Phase 2 | 72 | Costantine AlbanyOTHER | 2 | Jul 11, 2022 | clinicaltrials |
| NCT02582749 | Androgen Deprivation Therapy +/- Radium-223 Dichloride in Metastatic Prostate Cancer With Bone Metastases | terminated | Phase 2 | 16 | Ajjai Alva, MDOTHER | 1 | Jul 11, 2022 | clinicaltrials |
| NCT03964337 | Immediate Prostatectomy vs. Cabozantinib Followed by Prostatectomy in Men With High-Risk Prostate Cancer(SPARC) | terminated | Phase 2 | 3 | Duke UniversityOTHER | 1 | Jun 29, 2022 | clinicaltrials |
| NCT03367819 | Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies | terminated | Phase 1 / Phase 2 | 44 | SanofiINDUSTRY | 5 | May 16, 2022 | clinicaltrials |
| NCT02913131 | Hyperpolarized C-13 Pyruvate as a Biomarker in Patients With Advanced Solid Tumor Malignancies | terminated | Phase 1 / Phase 2 | 23 | Rahul AggarwalOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT02945813 | SAKK 08/15 - PROMET - Salvage Radiotherapy +/- Metformin for Patients With Prostate Cancer After Prostatectomy | terminated | Phase 2 | 112 | Swiss Cancer InstituteOTHER | 3 | Apr 14, 2022 | clinicaltrials |
| NCT02349386 | Maintaining Suppression of Testosterone With Transdermal Estradiol Gel(MASTERS) | terminated | Phase 2 | 34 | BHR Pharma, LLCINDUSTRY | 1 | Mar 31, 2022 | clinicaltrials |
| NCT04221828 | Trial of NanoPac Focal Therapy for Prostate Cancer | terminated | Phase 2 | 1 | NanOlogy, LLCINDUSTRY | 1 | Mar 29, 2022 | clinicaltrials |
| NCT02362451 | Multi-Epitope TARP Peptide Autologous Dendritic Cell Vaccination in Men With Stage D0 Prostate Cancer | terminated | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Mar 18, 2022 | clinicaltrials |
| NCT01650285 | Cabazitaxel and Radiation For Patients With Prostate Cancer | terminated | Phase 2 | 5 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT01650350 | Low Dose Naltrexone for Metastatic Melanoma, Castrate Resistant Prostate Cancer and Renal Cancer | terminated | Phase 2 | 7 | Brown UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT03441464 | Feasibility of the LUM Imaging System for Detection of Prostate Cancer | terminated | Phase 1 / Phase 2 | 9 | Lumicell, Inc.INDUSTRY | 1 | Feb 25, 2022 | clinicaltrials |
| NCT00594620 | Soy Derivatives for Control of Hot Flashes in Men on Androgen Deprivation Therapy | terminated | Phase 2 | 11 | University of Kansas Medical CenterOTHER | 1 | Feb 14, 2022 | clinicaltrials |
| NCT03689582 | Radiolabeled Gallium-68 (68Ga-PSMA) for PET/CT Imaging to Detect Prostate Cancer | terminated | Phase 2 | 11 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 5, 2022 | clinicaltrials |
| NCT02648919 | Clinical Study of Noni Extract in Men With Very Low Risk or Low Risk Prostate Cancer | terminated | Phase 2 | 6 | University of HawaiiOTHER | 1 | Nov 26, 2021 | clinicaltrials |
| NCT02506114 | Neoadjuvant PROSTVAC-VF With or Without Ipilimumab for Prostate Cancer | terminated | Phase 2 | 15 | Lawrence FongOTHER | 1 | Nov 24, 2021 | clinicaltrials |
| NCT03712930 | Treatment of Metastatic Castration-Resistant Prostate Cancer With Homologous Recombination Deficiency | terminated | Phase 2 | 13 | BeiGeneINDUSTRY | 4 | Nov 17, 2021 | clinicaltrials |
| NCT03886493 | Neoadjuvant Dupilumab in Men With Localized High-Risk Prostate Cancer | terminated | Phase 2 | 7 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 15, 2021 | clinicaltrials |
| NCT04052204 | Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors | terminated | Phase 1 / Phase 2 | 3 | PfizerINDUSTRY | 4 | Oct 14, 2021 | clinicaltrials |
| NCT02508636 | Trial of Radiotherapy With Leuprolide and Enzalutamide in High Risk Prostate Cancer | terminated | Phase 2 | 11 | University of California, San FranciscoOTHER | 1 | Oct 12, 2021 | clinicaltrials |
| NCT02565901 | Sirolimus, Docetaxel, and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 28 | University of WashingtonOTHER | 1 | Oct 1, 2021 | clinicaltrials |
| NCT03545165 | 177Lu-J591 and 177Lu-PSMA-617 Combination for mCRPC | terminated | Phase 1 / Phase 2 | 6 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 24, 2021 | clinicaltrials |
| NCT02985021 | Docetaxel and Carboplatin for Patients With mCRPC and DNA-Repair Deficiencies | terminated | Phase 2 | 2 | Seattle Institute for Biomedical and Clinical ResearchOTHER | 1 | Aug 5, 2021 | clinicaltrials |
| NCT02805894 | NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma | terminated | Phase 1 / Phase 2 | 5 | NanobiotixINDUSTRY | 1 | May 10, 2021 | clinicaltrials |
| NCT02685267 | Docetaxel/Prednisone Versus Docetaxel/Prednisone and Enzalutamide in Castration-Resistant Prostate Cancer(Doce/Enza) | terminated | Phase 2 | 9 | Prostate Cancer Clinical Trials ConsortiumOTHER | 1 | Apr 9, 2021 | clinicaltrials |
| NCT03042312 | Lutetium-177 (Lu177) Prostate-Specific Antigen (PSMA)-Directed EndoRadiotherapy(RESIST-PC) | terminated | Phase 2 | 71 | EndocyteINDUSTRY | 1 | Mar 24, 2021 | clinicaltrials |
| NCT03572478 | Rucaparib and Nivolumab in Patients With Prostate or Endometrial Cancer | terminated | Phase 1 / Phase 2 | 12 | University of ChicagoOTHER | 1 | Mar 9, 2021 | clinicaltrials |
| NCT03261336 | Oral Calcitriol With Ketoconazole in CRPC | terminated | Phase 2 | 1 | Donald Trump, MDOTHER | 1 | Feb 8, 2021 | clinicaltrials |
| NCT03741712 | A Study of SHR2554 Alone or in Combination With SHR3680 in the Treatment of mCRPC | terminated | Phase 1 / Phase 2 | 9 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Feb 5, 2021 | clinicaltrials |
| NCT03514836 | A Phase I/II, Safety Clinical Trial of DCVAC/PCa and ONCOS-102 in Men With Metastatic Castration-resistant Prostate Cancer | terminated | Phase 1 / Phase 2 | 5 | SOTIO a.s.INDUSTRY | 1 | Feb 1, 2021 | clinicaltrials |
| NCT02844582 | Cabazitaxel and Prednisone in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer | terminated | Phase 2 | 2 | University of California, DavisOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT00757757 | A Phase I/II Open-label Study of MCS110 in Patients With Prostate Cancer and Bone Metastases | terminated | Phase 1 / Phase 2 | 3 | Novartis PharmaceuticalsINDUSTRY | 1 | Dec 19, 2020 | clinicaltrials |
| NCT00780975 | A Study of Aplidin ( Plitidepsin) in Subjects With Advanced Prostate Cancer | terminated | Phase 2 | 8 | PharmaMarINDUSTRY | 1 | Nov 24, 2020 | clinicaltrials |
| NCT03724253 | [68Ga]-NeoBOMB1 Imaging in Patients With Malignancies Known to Overexpress Gastrin Releasing Peptide Receptor (GRPR)(NeoFIND) | terminated | Phase 2 | 19 | Advanced Accelerator ApplicationsINDUSTRY | 2 | Oct 23, 2020 | clinicaltrials |
| NCT01928485 | Green Tea Extract in Treating Patients With Low-Risk Prostate Cancer | terminated | Phase 2 | 6 | Sanjay Gupta PhDOTHER | 1 | Oct 22, 2020 | clinicaltrials |
| NCT00004026 | CT-2584 in Treating Patients With Metastatic Prostate Cancer That Has Not Responded to Previous Therapy | terminated | Phase 2 | 80 | CTI BioPharmaINDUSTRY | 1 | Oct 19, 2020 | clinicaltrials |
| NCT03570476 | Olaparib Before Surgery in Treating Participants With Localized Prostate Cancer | terminated | Phase 2 | 2 | University of WashingtonOTHER | 1 | Sep 21, 2020 | clinicaltrials |
| NCT02168062 | Supportive Therapy in Androgen Deprivation Clinic in Improving Health Outcomes and Managing Side Effects in Patients With Prostate Cancer | terminated | Phase 2 | 57 | University of California, San FranciscoOTHER | 1 | Jul 23, 2020 | clinicaltrials |
| NCT03827473 | Docetaxel or Abiraterone Acetate With ADT in Treating Patients With Metastatic Hormone Sensitive Prostate Cancer(ACADEMIC) | terminated | Phase 2 | 1 | University of UtahOTHER | 1 | Jun 25, 2020 | clinicaltrials |
| NCT01545882 | A Phase II Study of Degarelix in the Management of Non-Metastatic Hormone-Refractory Prostate Cancer(OTT10-06) | terminated | Phase 2 | 5 | Ottawa Hospital Research InstituteOTHER | 1 | May 7, 2020 | clinicaltrials |
| NCT03093272 | A Study of Docetaxel + ARN-509 in Castration-Resistant Prostate Cancer | terminated | Phase 2 | 9 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 9, 2020 | clinicaltrials |
| NCT03763851 | Cannabis Oil and Radiation Therapy for the Management of Pain | terminated | Phase 2 | 100 | Tetra Bio-PharmaINDUSTRY | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01499043 | Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC) | terminated | Phase 2 | 6 | Daiichi SankyoINDUSTRY | 1 | Mar 4, 2020 | clinicaltrials |
| NCT02311764 | Carboplatin in Castration-resistant Prostate Cancer(PRO-PLAT) | terminated | Phase 2 | 16 | Aurelius OmlinOTHER | 1 | Jan 23, 2020 | clinicaltrials |
Data updated 23 days agoSource updated Feb 8, 2023source: clinicaltrials